Strategic Merger Pulmatrix merged with Eos SENOLYTIX in early 2026, creating potential co development and cross-sell opportunities across respiratory and non-respiratory pipelines, expanding addressable markets and access to additional funding channels.

iSPERSE Advantage Leverage Pulmatrix’s proprietary iSPERSE inhalation technology to position as a partner for formulation optimization or co-development of inhaled therapies, including NSKIs and respiratory/non-respiratory applications.

Phase Pipeline Active Phase 1/2 activities around PUR3100 with ongoing discussions for Phase 2 financing or partnerships, presenting a near-term collaboration window for strategic investors or pharma partners seeking inhaled therapeutics.

Clinical Footprint Past and recent publications and Phase Ib results on PUR1800 and related DDI work demonstrate a credible safety and pharmacokinetic profile, enabling BD conversations with pharma and contract research organizations evaluating inhaled asset portfolios.

Commercial Readiness Milestones such as journal publications and expanded portfolio rights (PUr1800 reversion) indicate potential for accelerated licensing discussions, co marketing arrangements, or strategic partnerships to monetize inhaled therapies.